Testing effectiveness (Phase 2)UnknownNCT05466175What this trial is testingOlverembatinib in the Treatment of Ph+ ALLWho this might be right forPhiladelphia-Positive ALL Chen Suning 55
Early research (Phase 1)Looking for participantsNCT07250087What this trial is testingAsciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALLWho this might be right forPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia H. Lee Moffitt Cancer Center and Research Institute 36
Testing effectiveness (Phase 2)Study completedNCT01460160What this trial is testingPediatric Philadelphia Positive Acute Lymphoblastic LeukemiaWho this might be right forLeukemia, Pediatric Bristol-Myers Squibb 106
Not applicableLooking for participantsNCT07493161What this trial is testingChemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALLWho this might be right forPh+ ALL Institute of Hematology & Blood Diseases Hospital, China 110
Not applicableNo Longer AvailableNCT04559555What this trial is testingMAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaWho this might be right forAcute Lymphoblastic Leukemia (ALL) Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07443488What this trial is testingEfficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALLWho this might be right forHSCTPh+ ALL Institute of Hematology & Blood Diseases Hospital, China 20
Testing effectiveness (Phase 2)Ended earlyNCT03698552What this trial is testingADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaWho this might be right forBlasts 5 Percent or More of Bone Marrow Nucleated CellsCD22 PositivePhiladelphia Chromosome Positive+2 more M.D. Anderson Cancer Center 37
Early research (Phase 1)Active Not RecruitingNCT03233854What this trial is testingCD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell MalignanciesWho this might be right forB Acute Lymphoblastic LeukemiaCD19 PositiveMinimal Residual Disease+1 more Stanford University 56
Early research (Phase 1)Looking for participantsNCT04260022What this trial is testingStudy of HQP1351 in Subjects With Refractory CML and Ph+ ALLWho this might be right forLeukemia, Myeloid, ChronicMyeloid LeukemiaChronic Myeloid Leukemia+2 more Ascentage Pharma Group Inc. 242
Early research (Phase 1)Study completedNCT00316953What this trial is testingDasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib MesylateWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChildhood Chronic Myelogenous Leukemia+5 more National Cancer Institute (NCI) 48
Testing effectiveness (Phase 2)Study completedNCT00702403What this trial is testingNilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CMLWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionBlastic Phase Chronic Myelogenous Leukemia+11 more Fred Hutchinson Cancer Center 40
Testing effectiveness (Phase 2)Study completedNCT00298987What this trial is testingDasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib MesylateWho this might be right forLeukemia, Myeloid, ChronicLeukemia, Lymphocytic, Acute, L2 Bristol-Myers Squibb 400
Testing effectiveness (Phase 2)Study completedNCT01445080What this trial is testingSorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LeukemiaWho this might be right forBlastic PhaseChildhood Acute Promyelocytic Leukemia With PML-RARAChildhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive+7 more National Cancer Institute (NCI) 70
Testing effectiveness (Phase 2)Study completedNCT01030718What this trial is testingRollover Study of BMS-354825 in Patients With CML and Ph+ALLWho this might be right forChronic Myelogenous LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia Bristol-Myers Squibb 54
Early research (Phase 1)Study completedNCT00940524What this trial is testingInduction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic LeukemiaWho this might be right forLeukemiaAcute Lymphoblastic Leukemia Memorial Sloan Kettering Cancer Center 7
Not applicableUnknownNCT01185886What this trial is testingStudy of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic LeukemiaWho this might be right forLeukemiaLymphoma European Organisation for Research and Treatment of Cancer - EORTC 1,200
Early research (Phase 1)Looking for participantsNCT06287528What this trial is testing19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)Who this might be right forPhiladelphia-Negative ALLPhiladelphia-Positive ALLRelapsed ALL, Adult+3 more Memorial Sloan Kettering Cancer Center 18
Not applicableUnknownNCT02888977What this trial is testingTyrosine Kinase Inhibitors and Low Intensity Chemotherapy in Ph+ ALLWho this might be right forLymphoblastic Leukemia, Acute Versailles Hospital 100
Early research (Phase 1)Study completedNCT01925131What this trial is testingS1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute LeukemiaWho this might be right forAcute Leukemias of Ambiguous LineageB-cell Adult Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia+2 more SWOG Cancer Research Network 50
Testing effectiveness (Phase 2)UnknownNCT00008307What this trial is testingCombination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic DisordersWho this might be right forLeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more Herbert Irving Comprehensive Cancer Center 52